Lucy Scientific Discovery (NASDAQ: LSDI), a pioneer in alternative mental-health treatments, is working to provide ingredients for effective mental-health treatment and therapies, including psilocybin and MDMA. According to a recent article spotlighting LSDI, the company is “well positioned” to support the mental-health space as it continues to grow. The article noted that mental-health issues are … Continue reading “NetworkNewsBreaks – Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Strengthen Position in Alternative Mental-Health Treatments Sector”
Lucy Scientific Discovery (NASDAQ: LSDI) is an early-stage psychotropics manufacturing company focused on becoming the premier contract research, development and manufacturing organization for the emerging psychotropics-based medicines industry. The company holds a Controlled Drugs and Substances Dealer’s License granted by Health Canada’s Office of Controlled Substances. This specialized license authorizes LSDI to develop, sell, deliver … Continue reading “Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Is ‘One to Watch’”
Institute of Biomedical Research (OTC: MRES), DBA M2Bio Sciences, has appointed a new member to its advisory board. A distinguished leader and financial and data analytics expert, Adrian Maizey brings a rich background to his new board member role. Maizey has worked with top-tier companies around the world in an array of industries, from the … Continue reading “NetworkNewsBreaks – Institute of Biomedical Research Corp. (MRES) Names Veteran Financial Leader to Advisory Board”
Institute of Biomedical Research (OTC: MRES) (doing business as M2Bio Sciences) is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids, medical psilocybin and mental health therapeutic research powered by artificial intelligence and evidence-based sustainable products and solutions. M2Bio Sciences today announced the forthcoming launch of a captivating line of teas sourced from the scenic … Continue reading “NetworkNewsBreaks – Institute of Biomedical Research Corp. (MRES) Unveils Meticulously Crafted Line of Teas Sourced from Kenya”
Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the U.S. Patent and Trademark Office (“USPTO”) has issued U.S. Patent 16/825,371 titled “Peptide-Targeted Liposomal Delivery for Treatment, Diagnosis and Imaging of Diseases and Disorders.” According to the announcement, the new patent claims cover the … Continue reading “NetworkNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Secures US Patent for SPU-21 Treatment for Autoimmune Disease”
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has signed a letter of intent with Peter/PetraMD, the largest online provider of hormone therapy in the United States for the acquisition of Ketamine Wellness Centers. According to the announcement, the acquisition provides an incredible on-ramp … Continue reading “NetworkNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Inks LOI for Acquisition of Ketamine Wellness Centers”
Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused around merging traditional therapeutics with psychedelic research, recently announced that it had achieved a positive outcome for its toxicology study of SP-26, its novel time-released, dosage-controlled formulation of ketamine. The results come after Silo Pharma had previously revealed that it was working on the preparation … Continue reading “Silo Pharma Inc. (NASDAQ: SILO) Provides Update on Innovative Study Looking into the Feasibility of Using Ketamine Formulations as an Alternative Treatment for Fibromyalgia”
Silo Pharma (NASDAQ: SILO) is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. “Silo Pharma has distinguished itself amongst peers for its ground-breaking research into conditions such as post-traumatic stress disorder (‘PTSD’), fibromyalgia, Alzheimer’s disease, and other rare neurological disorders. The company has recently entered into a number of studies designed … Continue reading “NetworkNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Positioned as Frontrunner in Psychedelic Drugs Market”
In a study carried out between 2013 to 2016, researchers found that 8.1% of American adults aged 20 and over suffered from depression during any given 2-week period, with women nearly twice as likely than men to have had acute depression (https://nnw.fm/L3ZQN). Whilst depression has long been treated with a combination of self-help, talking therapies … Continue reading “Silo Pharma Inc. (NASDAQ: SILO) Set to Benefit as Study Supports the Efficacy of Psychedelics in Treating ‘Drug-Resistant’ Depression”
Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company, recently provided a progress update on its sponsored clinical trial with the University of California, San Francisco (“UCSF”) examining the effect of psilocybin on inflammation. “Silo’s sponsored clinical trial with the Clinical & Translational Science Institute at UCSF aims to validate the use of psilocybin as a … Continue reading “NetworkNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Partnering to Transform Health Care, Improve Patient Outcomes”
